肠道菌群在肿瘤免疫治疗中的作用研究进展

周彬; 尚付梅; 樊启林; 师琳丽; 吴晶晶; 刘红利

doi:10.3969/j.issn.1000-8179.2020.22.138

肠道菌群在肿瘤免疫治疗中的作用研究进展

doi: 10.3969/j.issn.1000-8179.2020.22.138

华中科技大学同济医学院附属协和医院肿瘤中心腹部肿瘤科(武汉市 430022)

基金项目:

国家重点研发计划项目 2018YFC1313300

详细信息

作者简介:
周彬专业方向为肠道菌群对腹部肿瘤免疫治疗的影响及机制研究。E-mail:zb17683715206@163.com

通讯作者:
刘红利 hongli_liu@hust.edu.cn

计量
- 文章访问数: 391
- HTML全文浏览量: 37
- PDF下载量: 146
- 被引次数: 0
出版历程
- 收稿日期: 2020-09-04
- 刊出日期: 2020-12-26

Research progress on the role of gut microbiome in tumor immunotherapy

Department of Abdominal Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Funds:

the National Key Research and Development Program of China 2018YFC1313300

More Information

Corresponding author: Hongli Liu; E-mail: hongli_liu@hust.edu.cn

摘要

摘要: 肠道微生物与肿瘤发生、发展关系密切。机体暴露于大量肠道菌群及其代谢产物中，构成机体的生态环境，肠道微生物通过多种途径参与肿瘤的发生与发展。肠道菌群在肿瘤的治疗中发挥重要作用。目前，肿瘤免疫检测点抑制剂在多种恶性肿瘤中的治疗取得重要突破，肠道微生物组对肿瘤免疫治疗，尤其是免疫检测点抑制剂的疗效产生重要影响。本文就近年来肠道菌群对肿瘤免疫治疗中的作用及影响展开综述，为免疫检测点抑制剂在肿瘤治疗中的应用提供参考。
- 肠道微生物 /
- 肿瘤 /
- 免疫治疗 /
- 免疫检测点抑制剂 /
- 研究进展
Abstract: Recent research has shown that gut microbiome is closely related to tumorigenesis. Our body is exposed to a large number of intestinal microbiome and its metabolites, which constitute the ecological environment of the organism. Gut microbiome is involved in the occurrence and development of cancer through several diverse mechanisms. Immune checkpoint inhibitors have recently made breakthroughs in treating various malignant tumors, and increasing evidence suggests that intestinal microbiome has an important effect on tumor immunotherapy, especially immune checkpoint inhibitors. This review focuses on the role and effect of gut microbiota on tumor immunotherapy in recent years to provide a reference for the application of immune checkpoint inhibitors in tumor therapy.
- intestinal microbiota /
- tumor /
- immunotherapy /
- immune checkpoint inhibitors /
- research progress

HTML全文

参考文献(30)

[1]	Laukens D, Brinkman BM, Raes J, et al. Heterogeneity of the gut microbiome in mice:guidelines for optimizing experimental design[J]. FEMS Microbiol Rev, 2016, 40(1):117-132. doi: 10.1093/femsre/fuv036
[2]	Haanen JB, Robert C. Immune Checkpoint Inhibitors[J]. Prog Tumor Res, 2015, 42:55-66.
[3]	Gopalakrishnan V, Helmink BA, Spencer CN, et al. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy[J]. Cancer Cell, 2018, 33(4):570-580. doi: 10.1016/j.ccell.2018.03.015
[4]	Rajagopala SV, Vashee S, Oldfield LM, et al. The human microbiome and cancer[J]. Cancer Prev Res (Phila), 2017, 10(4):226-234. doi: 10.1158/1940-6207.CAPR-16-0249
[5]	Jandhyala SM, Talukdar R, Subramanyam C, et al. Role of the normal gut microbiota[J]. World J Gastroenterol, 2015, 21(29):8787-8803. doi: 10.3748/wjg.v21.i29.8787
[6]	Chen J, Pitmon E, Wang K. Microbiome, inflammation and colorectal cancer[J]. Semin Immunol, 2017, 32:43-53. doi: 10.1016/j.smim.2017.09.006
[7]	Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J]. Cancer Cell, 2012, 21(4):504-516. doi: 10.1016/j.ccr.2012.02.007
[8]	Karin M, Greten FR. NF-kappaB:linking inflammation and immunity to cancer development and progression[J]. Nat Rev Immunol, 2005, 5(10):749-759. doi: 10.1038/nri1703
[9]	Cremonesi E, Governa V, Garzon J, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer[J]. Gut, 2018, 67(11):1984-1994. doi: 10.1136/gutjnl-2016-313498
[10]	Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J]. Science, 2015, 350(6264):1084-1089. doi: 10.1126/science.aac4255
[11]	López P, Gueimonde M, Margolles A, et al. Distinct Bifidobacterium strains drive different immune responses in vitro[J]. Int J Food Microbiol, 2010, 138(1-2):157-165.
[12]	Luu M, Visekruna A. Short-chain fatty acids:Bacterial messengers modulating the immunometabolism of T cells[J]. Eur J Immunol, 2019, 49(6):842-848. doi: 10.1002/eji.201848009
[13]	Alatrash G, Jakher H, Stafford PD, et al. Cancer immunotherapies, their safety and toxicity[J]. Expert Opin Drug Saf, 2013, 12(5):631-645. doi: 10.1517/14740338.2013.795944
[14]	Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy[J]. Nat Rev Cancer, 2007, 7(2):95-106. doi: 10.1038/nrc2051
[15]	Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function[J]. Science, 2008, 322(5899):271-275. doi: 10.1126/science.1160062
[16]	Hsu J, Hodgins JJ, Marathe M, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade[J]. J Clin Invest, 2018, 128(10):4654-4668. doi: 10.1172/JCI99317
[17]	Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors[J]. Cancer Treat Rev, 2016, 44:51-60. doi: 10.1016/j.ctrv.2016.02.001
[18]	Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J]. Ann Oncol, 2017, 28(6):1368-1379. doi: 10.1093/annonc/mdx108
[19]	Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis[J]. Nat Commun, 2016, 7:10391. doi: 10.1038/ncomms10391
[20]	Pezo RC, Wong M, Martin A. Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities[J]. Therap Adv Gastroenterol, 2019, 12:321907521.
[21]	Yi M, Yu S, Qin S, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors[J]. J Hematol Oncol, 2018, 11(1):47. doi: 10.1186/s13045-018-0592-6
[22]	Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J]. Science, 2015, 350(6264):1079-1084. doi: 10.1126/science.aad1329
[23]	Lee JA, Yoo SY, Oh HJ, et al. Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status[J]. Cancer Immunol Immunother, 2020.[Epub ahead of print]
[24]	Xu X, Lv J, Guo F, et al. Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway[J]. Front Microbiol, 2020, 11:814. doi: 10.3389/fmicb.2020.00814
[25]	Jin Y, Dong H, Xia L, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed ceath 1 immunotherapy in chinese patients with NSCLC[J]. J Thorac Oncol, 2019, 14(8):1378-1389. doi: 10.1016/j.jtho.2019.04.007
[26]	Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371):91-97. doi: 10.1126/science.aan3706
[27]	Elkrief A, El RL, Richard C, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors[J]. Oncoimmunology, 2019, 8(4):e1568812. doi: 10.1080/2162402X.2019.1568812
[28]	Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371):97-103. doi: 10.1126/science.aan4236
[29]	Tella SH, Mahipal A, Kommalapati A, et al. Evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma:evidence to date[J]. Onco Targets Ther, 2019, 12:10335-10342. doi: 10.2147/OTT.S214870
[30]	Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J]. J Immunother Cancer, 2019, 7(1):193. doi: 10.1186/s40425-019-0650-9